Leptin is essential for the hepatic fibrogenic response to chronic liver injury.

PubWeight™: 1.86‹?› | Rank: Top 3%

🔗 View Article (PMID 12127425)

Published in J Hepatol on August 01, 2002

Authors

Isabelle A Leclercq1, Geoffrey C Farrell, Rixt Schriemer, Graham R Robertson

Author Affiliations

1: Storr Liver Unit, Department of Medicine and Westmead Millennium Institute, University of Sydney at Westmead Hospital, NSW 2145, Australia. isabelle_leclercq@wmi.usyd.edu.au

Articles citing this

Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98

Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol (2006) 3.46

Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol (2011) 2.82

Nonalcoholic fatty liver disease. CMAJ (2005) 2.56

Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res (2008) 2.21

Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol (2012) 2.08

Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol (2011) 1.85

The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol (2013) 1.72

Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clin Exp Immunol (2003) 1.65

Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. FASEB J (2004) 1.61

Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol (2007) 1.59

Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res (2012) 1.51

The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol (2005) 1.49

Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology (2009) 1.48

Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. Dig Dis Sci (2009) 1.43

Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57BL/6 mice. Diabetes (2010) 1.43

Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut (2004) 1.42

Liver diseases and metabolic syndrome. J Gastroenterol (2008) 1.33

Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut (2005) 1.30

Development of nonalcoholic steatohepatitis in insulin-resistant liver-specific S503A carcinoembryonic antigen-related cell adhesion molecule 1 mutant mice. Gastroenterology (2008) 1.29

Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair (2013) 1.27

Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23

Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin Liver Dis (2009) 1.21

Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol (2012) 1.21

Fbxw7 regulates lipid metabolism and cell fate decisions in the mouse liver. J Clin Invest (2010) 1.17

Regulation of the fibrosis and angiogenesis promoter SPARC/osteonectin in human adipose tissue by weight change, leptin, insulin, and glucose. Diabetes (2009) 1.13

Leptin increases tissue inhibitor of metalloproteinase I (TIMP-1) gene expression by a specificity protein 1/signal transducer and activator of transcription 3 mechanism. Mol Endocrinol (2006) 1.09

Animal models for the study of liver fibrosis: new insights from knockout mouse models. Am J Physiol Gastrointest Liver Physiol (2011) 1.08

Adiponectin activation of AMPK disrupts leptin-mediated hepatic fibrosis via suppressors of cytokine signaling (SOCS-3). J Cell Biochem (2010) 1.07

Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol (2006) 1.03

New insights from rodent models of fatty liver disease. Antioxid Redox Signal (2011) 1.03

Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis. Am J Pathol (2011) 1.01

Apo-10'-lycopenoic acid, a lycopene metabolite, increases sirtuin 1 mRNA and protein levels and decreases hepatic fat accumulation in ob/ob mice. J Nutr (2012) 0.97

Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis. Mol Med (2011) 0.95

Role of adipose tissue in methionine-choline-deficient model of non-alcoholic steatohepatitis (NASH). Biochim Biophys Acta (2014) 0.95

Histamine regulation in glucose and lipid metabolism via histamine receptors: model for nonalcoholic steatohepatitis in mice. Am J Pathol (2010) 0.95

Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. World J Gastroenterol (2014) 0.94

Leptin in hepatocellular carcinoma. World J Gastroenterol (2010) 0.93

Potential involvement of leptin in carcinogenesis of hepatocellular carcinoma. World J Gastroenterol (2004) 0.93

Curcumin eliminates leptin's effects on hepatic stellate cell activation via interrupting leptin signaling. Endocrinology (2009) 0.92

Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame. Dig Dis Sci (2015) 0.91

Leptin administration exacerbates thioacetamide-induced liver fibrosis in mice. World J Gastroenterol (2005) 0.90

Curcumin prevents leptin raising glucose levels in hepatic stellate cells by blocking translocation of glucose transporter-4 and increasing glucokinase. Br J Pharmacol (2010) 0.90

Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats. Gut (2006) 0.89

Leptin deficiency contributes to the pathogenesis of alcoholic fatty liver disease in mice. Am J Pathol (2012) 0.88

CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH). Semin Immunopathol (2013) 0.87

Curcumin protects hepatic stellate cells against leptin-induced activation in vitro by accumulating intracellular lipids. Endocrinology (2010) 0.86

Curcumin eliminates the effect of advanced glycation end-products (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signaling. Lab Invest (2014) 0.84

Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. Sci Rep (2015) 0.84

Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis. World J Gastroenterol (2015) 0.83

Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis. World J Gastroenterol (2009) 0.83

Increased levels of serum leptin are a risk factor for the recurrence of stage I/II hepatocellular carcinoma after curative treatment. J Clin Biochem Nutr (2011) 0.83

Serum leptin levels, hepatic leptin receptor transcription, and clinical predictors of non-alcoholic steatohepatitis in obese bariatric surgery patients. Surg Endosc (2007) 0.82

An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study. BMC Gastroenterol (2007) 0.82

Potential for Dietary ω-3 Fatty Acids to Prevent Nonalcoholic Fatty Liver Disease and Reduce the Risk of Primary Liver Cancer. Adv Nutr (2015) 0.81

Genetic polymorphisms in non-alcoholic fatty liver disease: clues to pathogenesis and disease progression. World J Gastroenterol (2009) 0.81

The goose genome sequence leads to insights into the evolution of waterfowl and susceptibility to fatty liver. Genome Biol (2015) 0.80

AMPK Activation by Metformin Suppresses Abnormal Extracellular Matrix Remodeling in Adipose Tissue and Ameliorates Insulin Resistance in Obesity. Diabetes (2016) 0.80

Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice. PLoS One (2015) 0.80

Leptin in the field of hepatic fibrosis: a pivotal or an incidental player? Dig Dis Sci (2006) 0.80

Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-/- mice. Proc Nutr Soc (2015) 0.79

Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. J Res Med Sci (2016) 0.77

Over-expression of catalase in myeloid cells confers acute protection following myocardial infarction. Int J Mol Sci (2014) 0.77

Hepatic DNA hydroxymethylation is site-specifically altered by chronic alcohol consumption and aging. Eur J Nutr (2015) 0.77

NGF and P75NTR gene expression is associated with the hepatic fibrosis stage due to viral and non-viral causes. PLoS One (2015) 0.76

Curcumin targets multiple pathways to halt hepatic stellate cell activation: updated mechanisms in vitro and in vivo. Dig Dis Sci (2014) 0.75

Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol (2016) 0.75

Western diet-induced hepatic steatosis and alterations in the liver transcriptome in adult Brown-Norway rats. BMC Gastroenterol (2015) 0.75

How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease? Front Endocrinol (Lausanne) (2016) 0.75

Study on the Antifibrotic Effects of Recombinant Shark Hepatical Stimulator Analogue (r-sHSA) in Vitro and in Vivo. Mar Drugs (2015) 0.75

Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and Immunity. PLoS One (2016) 0.75

Pathologic Impact of Insulin Resistance and Sensitivity on the Severity of Liver Histopathology in Pediatric Non-Alcoholic Steatohepatitis. Yonsei Med J (2017) 0.75

Loss of pericyte smoothened activity in mice with genetic deficiency of leptin. BMC Cell Biol (2017) 0.75

Serum leptin levels correlate with body mass index but not with histologic disease severity in Indian patients with non-alcoholic steatohepatitis: a pilot study. Indian J Med Res (2013) 0.75

Adipokines in Liver Cirrhosis. Int J Mol Sci (2017) 0.75

Articles by these authors

The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology (2002) 4.44

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology (2003) 4.10

Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology (2004) 3.93

Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol (2008) 2.72

Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology (2013) 2.64

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology (2002) 2.51

Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology (2003) 2.40

Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol (2007) 2.37

Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology (2007) 2.36

Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology (2003) 2.28

Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology (2011) 2.05

Hepatic ischemia reperfusion injury: pathogenic mechanisms and basis for hepatoprotection. J Gastroenterol Hepatol (2003) 2.02

Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos (2008) 1.77

Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res (2006) 1.64

Diannexin, a novel annexin V homodimer, provides prolonged protection against hepatic ischemia-reperfusion injury in mice. Gastroenterology (2007) 1.63

Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology (2011) 1.52

Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology (2004) 1.49

Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol (2002) 1.41

Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? J Hepatol (2005) 1.31

Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology (2006) 1.28

Hepatic free fatty acids accumulate in experimental steatohepatitis: role of adaptive pathways. J Hepatol (2008) 1.26

COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator. Hepatology (2006) 1.25

Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J Gastroenterol Hepatol (2004) 1.24

Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology (2004) 1.24

HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology (2002) 1.23

A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol (2010) 1.23

MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. J Hepatol (2008) 1.22

Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol (2011) 1.21

Hepatotoxic slimming aids and other herbal hepatotoxins. J Gastroenterol Hepatol (2008) 1.21

Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol (2002) 1.21

Publications from China: the sleeping giant awakens. J Gastroenterol Hepatol (2008) 1.14

Leptin-specific mechanisms for impaired liver regeneration in ob/ob mice after toxic injury. Gastroenterology (2003) 1.08

Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol (2004) 1.07

Src tyrosine kinase phosphorylation of nuclear receptor HNF4α correlates with isoform-specific loss of HNF4α in human colon cancer. Proc Natl Acad Sci U S A (2012) 1.07

Pregnane X receptor: promiscuous regulator of detoxification pathways. Int J Biochem Cell Biol (2006) 1.06

Probing Prometheus: fat fueling the fire? Hepatology (2004) 1.06

Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem Biophys Res Commun (2006) 1.04

Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol (2008) 1.02

Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J Hepatol (2013) 1.02

MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecol Oncol (2005) 1.00

Ethanol reduces p38 kinase activation and cyclin D1 protein expression after partial hepatectomy in rats. J Hepatol (2005) 0.99

Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. J Gastroenterol Hepatol (2009) 0.98

Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol (2004) 0.96

Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol (2005) 0.96

Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol (2008) 0.95

New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol (2007) 0.95

Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. J Gastroenterol Hepatol (2012) 0.94

Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation. J Gastroenterol Hepatol (2007) 0.94

NADPH oxidase is not an essential mediator of oxidative stress or liver injury in murine MCD diet-induced steatohepatitis. J Hepatol (2006) 0.93

Liver membrane proteome glycosylation changes in mice bearing an extra-hepatic tumor. Mol Cell Proteomics (2010) 0.93

A truncating mutation of Alms1 reduces the number of hypothalamic neuronal cilia in obese mice. Dev Neurobiol (2012) 0.92

HNF4α: a new biomarker in colon cancer? Biomark Med (2012) 0.92

Prevention of hepatocellular carcinoma complicating chronic hepatitis C. J Gastroenterol Hepatol (2009) 0.92

Short-term therapy with peroxisome proliferation-activator receptor-alpha agonist Wy-14,643 protects murine fatty liver against ischemia-reperfusion injury. Hepatology (2010) 0.91

Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. J Hepatol (2004) 0.91

Fatty liver now, diabetes and heart attack later? The liver as a barometer of metabolic health. J Gastroenterol Hepatol (2007) 0.91

Prevention of hepatocellular carcinoma in nonviral-related liver diseases. J Gastroenterol Hepatol (2009) 0.90

High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD. Hepatology (2004) 0.89

Individualisation of antiviral therapy for chronic hepatitis C. J Gastroenterol Hepatol (2010) 0.89

Drug-induced cholestasis. Expert Opin Drug Saf (2003) 0.89

VAT fat is bad for the liver, SAT fat is not! J Gastroenterol Hepatol (2008) 0.89

How should we manage patients with non-alcoholic fatty liver disease in 2007? J Gastroenterol Hepatol (2007) 0.88

Hepatotoxicity associated with non-steroidal anti-inflammatory drugs. Clin Liver Dis (2003) 0.88

Liver cholesterol: is it playing possum in NASH? Am J Physiol Gastrointest Liver Physiol (2012) 0.88

Coffee and non-alcoholic fatty liver disease: brewing evidence for hepatoprotection? J Gastroenterol Hepatol (2014) 0.87

Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly. Curr Gerontol Geriatr Res (2011) 0.86

Cyclin E facilitates dysplastic hepatocytes to bypass G1/S checkpoint in hepatocarcinogenesis. J Gastroenterol Hepatol (2013) 0.84

Drugs and the liver updated, 2002. Semin Liver Dis (2002) 0.84

Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease. Obesity (Silver Spring) (2013) 0.84

Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging (Albany NY) (2012) 0.84

Primary biliary cirrhosis in Asians: less common than in Europeans, but just as depressing. J Gastroenterol Hepatol (2008) 0.84

Proteomic comparison of colorectal tumours and non-neoplastic mucosa from paired patient samples using iTRAQ mass spectrometry. Mol Biosyst (2011) 0.84

Extrahepatic cancer suppresses nuclear receptor-regulated drug metabolism. Clin Cancer Res (2011) 0.83

PNPLeAse get the fats right: does lipogenesis or lipolysis cause NASH? Hepatology (2010) 0.81

Will non-invasive markers replace liver biopsy for diagnosing and staging fibrosis in non-alcoholic steatohepatitis? J Gastroenterol Hepatol (2009) 0.81

Classification of cancer patients using pathway analysis and network clustering. Methods Mol Biol (2011) 0.80

Histological features of non-alcoholic fatty liver disease: what is important? J Gastroenterol Hepatol (2012) 0.80

TNF-alpha as therapeutic target in NASH: tried, but not yet proven. J Gastroenterol Hepatol (2007) 0.79

Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression. Am J Gastroenterol (2003) 0.78

Predicting inductive drug-drug interactions. Pharmacogenomics (2003) 0.78

Identifying who is at risk of drug-induced liver injury: is human leukocyte antigen specificity the key? Hepatology (2011) 0.78

Extra-hepatic cancer represses hepatic drug metabolism via interleukin (IL)-6 signalling. Pharm Res (2013) 0.78

Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C. Liver Int (2005) 0.78

Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting. Med J Aust (2003) 0.78

Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance. Am J Gastroenterol (2002) 0.77

Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis. Biochem Biophys Res Commun (2007) 0.77

Pretranslational upregulation of microsomal CYP4A in rat liver by intake of a high-sucrose, lipid-devoid diet containing orotic acid. Biochem Pharmacol (2004) 0.77

The alternatively spliced murine pregnane X receptor isoform, mPXR(delta171-211) exhibits a repressive action. Int J Biochem Cell Biol (2010) 0.77

Does non-alcoholic fatty liver disease predispose patients to type 2 diabetes in the absence of obesity? J Gastroenterol Hepatol (2010) 0.77

A novel approach to investigate the subcellular distribution of nuclear receptors in vivo. Nucl Recept Signal (2009) 0.76

Clues from the carotids: an appraisal of cardiovascular disease risk in non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2009) 0.76

Hepatic endoplasmic reticulum stress in obesity: deeper insights into processes, but are they relevant to nonalcoholic steatohepatitis? Hepatology (2011) 0.76

Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them. J Gastroenterol Hepatol (2003) 0.76

Emerging leaders of gastroenterology and hepatology in the Asia-Pacific region. J Gastroenterol Hepatol (2007) 0.75

Lessons from Lumiracoxib: are cyclooxygenase-2 inhibitors less hepatotoxic than non-selective non-steroidal anti-inflammatory drugs? J Gastroenterol Hepatol (2012) 0.75

Liver regeneration in obese mice with fatty livers: does the impairment have relevance for other types of fatty liver disease? Hepatology (2002) 0.75

The maturation of the Journal of Gastroenterology and Hepatology ( JGH) and the JGH Foundation. J Gastroenterol Hepatol (2006) 0.75